Two deaths halt Re­gen­eron’s prostate can­cer bis­pe­cif­ic an­ti­body tri­al as it looks at tweak­ing com­bo plans

Re­gen­eron is ex­plor­ing next steps with its PS­MA/CD28 bis­pe­cif­ic an­ti­body de­vel­op­ment in prostate can­cer af­ter two pa­tient deaths in a com­bo tri­al with Lib­tayo. The …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER